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Introduction: Current guidelines do not mention tacrolimus (TAC)
as a treatment option and no consensus has been reported on the
role of tacrolimus in active LN. Recent clinical trials have reported
positive effects of tacrolimus-based regimens for treatment of lupus
nephritis (LN). In order to translate these trials into clinical prac-
tice, we systematically reviewed all clinical studies published thus
far that investigated TAC regimens in LN patients and performed a
meta-analysis.
Methods:We identiﬁed from various databases every clinical study
investigating TAC regimens in LN. Studies were summarized on the
basis of treatment target (induction or maintenance), concomitant
immunosuppression and quality of the data. A meta-analysis was
performed for the efﬁcacy of TAC regimens as induction treatment.
Results: 239 studies were identiﬁed from which 24 were clinical
studies performed in LN patients: 6 case series, 9 cohort studies, 3
case-control studies (CCS) and 6 randomized controlled trials
(RCTs). Further analysis of the 9 controlled trials showed that 7
studies investigated tacrolimus in combination with steroids and 2
tacrolimus with mycophenolate plus steroids. 4 RCTs investigated
TAC regimens as induction treatment and 2 RCTs as maintenance
treatment. Strikingly, there was no consensus in any of the studies
regarding tacrolimus dosing and target trough levels. Importantly,
all the studies were performed in LN patients of Asian ethnicity. A
meta-analysis of TAC regimens for induction treatment showed a
signiﬁcantly higher complete response (RR 1.18, 95% CI 1.04-1.34,
p ¼ 0.01) and a signiﬁcantly lower no response rate (RR 0.71, 95%
CI 0.56-0.90, p<0.01). With respect to safety, no clear differences
between TAC regimens and conventional treatment were observed.
Conclusions: Current studies on TAC regimens for LN are limited,
heterogeneous and predominant uncontrolled studies in patients of
Asian ethnicity. A signiﬁcant clinical efﬁcacy of TAC regimens as
induction treatment was found. However, this cannot be extrapo-
lated beyond Asian LN patient groups. Clearly, these results
mandate further conﬁrmation in multi-ethnic, randomized trials.
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Introduction: Human renal microvascular endothelial cells (RMEC)
normally express high levels of HLA class II, even when no
inﬂammation is present by histology. Previous work in the lab with
isolated (cultured) RMEC showed that the cells present peptide in a
DR restricted manner to activate antigen-speciﬁc T cells. T cell
proliferation and cytokine secretion were decreased by CD40 and
CD58 antibodies and increased with CD274 (PD-L1) antibodies. We
hypothesized that RMEC express T cell inhibitory molecules in
vivo to prevent or limit T cell activation to HLA class II presented
peptides.
Nivolumab, a programed death 1 (PD1) inhibitor, is a new
immunotherapy option for a growing number of cancer types,
including lung cancer, advanced renal cell carcinoma, and meta-
static melanoma. It selectively binds PD1 to prevent interactionS14with its ligands PD-L1 (CD274, B7H1) and PD-L2 (CD273, B7H2).
PD-1 is expressed on activated T and B lymphocytes and myeloid
cells. Binding to its ligands transmits an inhibitory signal which
reduces the proliferation of these cells. Expression of PD1 ligands
on tumor cells enables them to suppress lymphocyte responses to
tumor antigens. Monoclonal antibodies targeting PD1 removes this
suppression, thereby enhancing T-cell responses to promote anti-
tumor activity.
Methods: Flow cytometry was used to identify RMEC and assess
their expression of PD1 ligands and T cell co-stimulatory proteins.
Medical records and pathology slides were reviewed for patients
who developed acute kidney injury while being treated with
nivolumab.
Results: Flow cytometry studies identiﬁed high levels of PD-L1 on
RMEC from normal human kidneys.
Four patients were identiﬁed who developed acute kidney
injury while receiving PD1 blocking antibody therapy for their
cancers. Three underwent renal biopsy which showed interstitial
nephritis with intense inﬂammation around capillaries. Other cau-
ses of interstitial nephritis were not identiﬁed from clinical history.
Conclusions: Our interpretation of RMEC’s ability to activate T
cells in a class II-peptide dependent manner, their high levels of
inhibitory ligand PD-L1 (CD274) and now the development of
interstitial inﬂammation in some patients receiving anti-PD1
monoclonal therapy is that RMEC are poised to present peptide
from circulating antigen as an immune surveillance system, with
the PD1 pathway functioning to restrain T cell activation. Other
human organs also express high levels of HLA class II on micro-
vascular endothelial cells. Hence our hypothesis of a kidney
capillary endothelium forming an immune surveillance system may
also pertain to other organs.
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Introduction: Chronic kidney disease (CKD) is a major risk factor for
cardiovascular disease (CVD), partly due to endothelial dysfunc-
tion, and chronic inﬂammation. Disturbed function of the immune
system in CKD patients is witnessed through the high levels of
cytokines in the plasma, and epigenetic modiﬁcations such as micro
RNAs (miRs) expression contribute to the disease process. Vitamin
D supplementation or treatment, protect endothelial function and
may improve outcome in these patients. In the SOLID-trial, we
showed that treatment with a vitamin D receptor activator, (VDRA;
paricalcitol) is followed by a maintained endothelial function and
capillary blood ﬂow. Here, we report the effect of paricalcitol on
pro-inﬂammatory cytokines and miRs in plasma from patients in
the SOLID-trial.
Methods: 36 patients with eGFR of 15-59 mL/min/1.73 m2, calcium
< 2.6 mmol/L, and PTH level of 35-500 pg/mL were randomized
to 12 weeks treatment with placebo, 1 mg, or 2 mg paricalcitol.Kidney International Reports (2016) 1, S1–S22
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016Pro-inﬂammatory molecules; basic FGF, VEGF, PDGF-88, IL1, IL6,
TNF, IL17a, IL8, MCP1, IP10, MIP1, MIP1, Eotaxin, RANTES, IL2,
IL4, IL5, IL9,IL12, IL13, IL15, IFN, G-CSF, GM-CSF, IL7, IL10 were
measured in plasma by Milliplex 26-plex. Total RNA was isolated
from plasma and the proﬁle of miRs was determined by Real-time
quantitative RT-PCR analysis. We calculated an integrated index
using endothelial function, cytokine levels, and miR data, to look at
the relation between laboratory and clinical data following
treatment.
Results: Leukocyte and platelet counts, CRP and serum albumin
levels were similar before and after treatment. The groups did not
differ in eGFR, Ca, P, and 25-OH-vitamin D3 levels after treatment,
but there was a dose dependent response in PTH levels. Since the
number of patients was small, we merged both treatment groups (1
and 2 mg) for the analysis. VEGF, PDGF, Basic-FGF, Eotaxin, IL8,
IP10, MIP1 , IFN , IL9, IL12, IL7, IL17, G-CSF, and IL10 decreased
signiﬁcantly following the treatment, compared to placebo, as did
miR 432-5p, miR 495-3p, and miR 576-5p. The integrated index
showed a signiﬁcant relation between macro- and microvascular
endothelial function and microcirculation, with cytokines such as
basic-FGF, PDGF and VEGF, together with miR 432. In terms of miR
495, the integrated value showed signiﬁcance for microvascular
endothelial function.
Conclusions: Paricalcitol treatment in moderate CKD reduces
inﬂammation and levels of selected miRs, involved in the athero-
sclerosis process and platelet function. The decline in cytokines and
miRs could be linked to our previous clinical ﬁndings, using the
integrated index. This study suggests a role for VDRA in patients
with moderate CKD but further studies are warranted to more
deeply characterize the effects of vitamin D on immune and
endothelial cells, expression of cytokines and regulation of miRs in
the process of the disease
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Introduction: The relationship between microbiota-induced TH17
cells in the small intestine and pathogenic TH17 responses in
autoimmune diseases is still unclear.
Methods: Renal TH17 cells from patients with ANCA-associated
glomerulonephritis and nephritic mice using the nephrotoxic
nephritis model (NTN) were analyzed by ﬂow cytometry including
intracellular cytokine staining. Migration of T cells in nephritic
mice was analyzed using photoconvertible Kaede-transgenic mice.
Results: Here, we report high frequencies of CD4+RORgt+TH17
cells in the kidneys of patients with ANCA-associated crescentic
glomerulonephritis and in a mouse model of crescentic glomerulo-
nephritis. By labeling intestinal cells in photoconvertible Kaede-
transgenic mice, we were able to demonstrate that a signiﬁcant
proportion of the TH17 cells in the inﬂamed kidney originated from
the small intestine and inﬁltrated the kidney via the CCR6/CCL20
axis. In line, experiments in germ free mice and in mice treatedKidney International Reports (2016) 1, S1–S22with a cocktail of four antibiotics revealed that the TH17 response
in the kidney and the consecutive tissue injury in crescentic
glomerulonephritis depended on microbiota-induced intestinal
TH17 cells. Furthermore, in a therapeutic and well-tolerable
approach, treatment of mice with a single antibiotic (vancomycin)
signiﬁcantly reduced intestinal TH17 cells and subsequently renal
TH17 inﬁltration and tissue damage.
Conclusions: These ﬁndings identiﬁed a direct relationship be-
tween microbiota-induced TH17 cells and the destructive TH17
response in autoimmunity, suggesting that therapeutic manipula-
tion of the intestinal microbiota might provide new opportunities
for the treatment of TH17-driven autoimmune disorders.
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Introduction: Systemic and local immune responses of leukocytes
are important for host defense, but uncontrolled inﬂammation can
lead to various organopathy. In addition, once cross reaction has
formed between the external antigen and the autoantigen, various
autoimmune diseases and allergic diseases can be induced. PILR
expressed mainly on macrophages, dendritic cells and gran-
ulocytes, contains two immunoreceptor tyrosine-based inhibitory
motifs (ITIMs) in its cytoplasmic domain. PILR has described for its
negative regulatory functions for activation of leukocyte 2 integrin
in acute inﬂammation including LPS-induced endotoxin shock
model. Here, we investigated roles of PILR in antibody-mediated
glomerular inﬂammation.
Methods: Antibody-mediated glomerulonephritis was induced by
intravenous administration of nephrotoxic serum (NTS) after pre-
immunization with rabbit IgG in C57BL/6 (WT) and PILR -/- mice.
Functional analysis for renal injury was performed by urine albu-
min and serum creatinine (sCr) concentrations at day 7, 14 and 21.
Diseased kidneys from both mouse strains were harvested for his-
tology, renal leukocyte inﬁltrates by ﬂow cytometry and renal
cytokine proﬁles by ELISA after induction of glomerulonephritis.
In vitro, m2 integrin-dependent neutrophil adhesion on immune-
complex (IC) formed with BSA-anti BSA IgG was evaluated in both
mouse strains.
Results: PILR was speciﬁcally expressed on glomerular Ly6B+cells
(neutrophils and monocytes) in diseased WT mice. Similar amount
of pathogenic rabbit IgG deposition on GBM was observed in WT
and PILR -/- mice on day 14 kidney specimen, but BUN and sCr
concentrations were signiﬁcantly elevated in PILR -/- mice compare
to WT mice at day 14 and 21, and those were highly associated with
deteriorated proteinuria. In histological analysis, glomerular dam-
ages, corroborated with both glomerular PAS deposits and
glomerular crescent formation, were signiﬁcantly severe in PILR -/-
mice at day 14 and 21 (p<0.05). Moreover, glomerular neutrophil
accumulation was remarkably observed in PILR -/- mice compare to
WT mice. In addition, total inﬁltration of Ly6Ghigh neutrophils,
F4/80+ macrophages and CD3+CD4+ T cells in whole kidneys were
increased in PILR -/- mice than WT mice at day 14 and 21. Renal
proinﬂammatory cytokine proﬁles for IL-1 and IL-6 on day 21 also
demonstrated severe renal inﬂammation in PILR -/-mice. In vitro,S15
